Modern approaches to diagnosis and treatment of vestibular migraine
https://doi.org/10.17650/1818-8338-2025-19-2-K741
Abstract
Vestibular migraine (VM) is a common but underdiagnosed form of migraine. The incidence of VM according to various population studies is about 3 %. Like other forms of migraines, VM is more common in women, especially of periand postmenopausal age. Apart from headaches and dizziness being the most frequent complaints to neurologists, according to the latest statistical data VM is also the most common cause of episodic vertigo. Currently, there aren’t any instrumental diagnostic methods that could confirm presence or absence of vestibular migraine. Diagnosis of this disease is based on results of clinical examination and anamnesis of the patient. Diagnostic criteria, jointly developed by the International Headache Society and the Barany Society, make it possible to diagnose probable or definitive vestibular migraine based exclusively on clinical and anamnestic data. Therapy of VM is based on the same principles as other migraines: relief of attacks and preventive therapy aimed at reducing the severity and frequency of the attacks. However, there are not enough studies on the effectiveness of classical antimigraine therapy in vestibular migraine, and currently in the medical community there are no generally accepted guidelines on treatment of this disease. Despite this, due to the accumulated experience of previous years, possibilities of vestibular migraine therapy are quite extensive and can be effectively applied in routine clinical practice of a neurologist.
About the Authors
S. S. Masueva
I.V. Davydovskiy City Clinical Hospital, Moscow Healthcare Department; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Seda Salakhovna Masueva
11/6 Yauzskaya Naberezhnaya, Moscow 109240, Russia; Build. 1, 2/1 Barrikadnaya St., Moscow 125993, Russia
M. V. Zamergrad
I.V. Davydovskiy City Clinical Hospital, Moscow Healthcare Department; Russian Gerontological Scientific and Clinical Center of N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
11/6 Yauzskaya Naberezhnaya, Moscow 109240, Russia; 161st Leonova St., Moscow 129226, Russia
S. P. Grachev
I.V. Davydovskiy City Clinical Hospital, Moscow Healthcare Department; Russian University of Medicine, Ministry of Health of Russia
Russian Federation
Russian Federation
11/6 Yauzskaya Naberezhnaya, Moscow 109240, Russia; Build. 1, 20 Delegatskaya St., Moscow 127473, Russia
References
1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38(1):1–211. DOI: 10.1177/0333102417738202
2. Bisdorff A., Von Brevern M., Lempert T., Newman-Toker D.E. Classification of vestibular symptoms: towards an international classification of vestibular disorders. J Vestib Res 2009;19(1–2): 1–13. DOI: 10.3233/VES-2009-0343
3. Calhoun A.H., Ford S., Pruitt A.P., Fisher K.G. The point prevalence of dizziness or vertigo in migraine and factors that influence presentation. Headache 2011;51(9):1388–92. DOI: 10.1111/j.1526-4610.2011.01970
4. Kang B.C., Kim T., Kwon J.K. Prevalence of vestibular migraine in an otolaryngologic clinic: preliminary clinical diagnosis versus diagnosis according to the strictly applied Bárány criteria. J Vestib Res 2023;33(2):137–42. DOI: 10.3233/VES-220112
5. Carvalho G.F., Vianna-Bell F.H., Florencio L.L. et al. Presence of vestibular symptoms and related disability in migraine with and without aura and chronic migraine. Cephalalgia 2019;39(1):29–37. DOI: 10.1177/0333102418769948
6. Huang T.C., Wang S.J., Kheradmand A. Vestibular migraine: an update on current understanding and future directions. Cephalalgia 2020;40(1):107–21. DOI: 10.1177/0333102419869317
7. Celebisoy N., Kısabay Ak А., Еzdemir H.N. et al. Vestibular migraine, demographic and clinical features of 415 patients: a multicenter study. Clin Neurol Neurosurg 2022;215:107201. DOI: 10.1016/j.clineuro.2022.107201
8. Strupp M., Dlugaiczyk J., Ertl-Wagner B.B. et al. Vestibular disorders. Dtsch Arztebl Int 2020;117(17):300–10. DOI: 10.3238/arztebl.2020.0300
9. Lempert T., Olesen J., Furman J. et al. Vestibular migraine: diagnostic criteria1. J Vestib Res 2022;32(1):1–6. DOI: 10.3233/VES-201644
10. Teggi R., Colombo B., Albera R. et al. Clinical features, familial history, and migraine precursors in patients with definite vestibular migraine: the VM-phenotypes projects. Headache 2018;58(4): 534–44. DOI: 10.1111/head.13240
11. Young A.S., Nham B., Bradshaw A.P. et al. Clinical, oculographic, and vestibular test characteristics of vestibular migraine. Cephalalgia 2021;41(10):1039–52. DOI: 10.1177/03331024211006042
12. Wattiez A.S., O’Shea S.A., Ten Eyck P. et al. Patients with vestibular migraine are more likely to have occipital headaches than those with migraine without vestibular symptoms. Headache 2020;60(8):1581–91. DOI: 10.1111/head.13898
13. Cha Y.H., Lee H., Santell L.S., Baloh R.W. Association of benign recurrent vertigo and migraine in 208 patients. Cephalalgia 2009;29(5):550–5. DOI: 10.1111/j.1468-2982.2008.01770
14. Guerra-Jiménez G., Arenas Rodríguez A., Falcón González J.C. et al. Epidemiology of vestibular disorders in the otoneurology unit. Acta Otorrinolaringol Esp (Engl Ed) 2017;68(6):317–22. DOI: 10.1016/j.otorri.2017.01.007
15. Dieterich M., Obermann M., Celebisoy N. Vestibular migraine: the most frequent entity of episodic vertigo. J Neurol 2016;263(1):82–9. DOI:10.1007/s00415-015-7905-2
16. Perez-Carpena P., Lopez-Escamez J.A. Do we need to reconsider the classification of vestibular migraine? Expert Rev Neurother 2021;21(5):503–16. DOI: 10.1080/14737175.2021
17. Casani A.P., Sellari-Franceschini S., Napolitano A. et al. Otoneurologic dysfunctions in migraine patients with or without vertigo. Otol Neurotol 2009;30(7):961–7. DOI: 10.1097/MAO.0b013e3181b4e780
18. Radtke A., von Brevern M., Neuhauser H. et al. Vestibular migraine: long-term follow-up of clinical symptoms and vestibulocochlear findings. Neurology 2012;79(15):1607–14. DOI: 10.1212/WNL.0b013e31826e264f
19. Von Brevern M., Zeise D., Neuhauser H. et al. Acute migrainous vertigo: сlinical and oculographic findings. Brain 2005;128(2): 365–74. DOI: 10.1093/brain/awh351
20. Carmona S., Zalazar G.J., Fernandez M. et al. Atypical positional vertigo: definition, causes, and mechanisms. Audiol Res 2022;12(2):152–61. DOI: 10.3390/audiolres12020018
21. Polensek S.H., Tusa R.J. Nystagmus during attacks of vestibular migraine: an aid in diagnosis. Audiol Neurootol 2010;15(4):241–6. DOI: 10.1159/000255440
22. Jeong S.H., Oh S.Y., Kim H.J. et al. Vestibular dysfunction Lection in migraine: effects of associated vertigo and motion sickness. J Neurol 2009;257(6):905–12. DOI: 10.1007/s00415-009-5435-5
23. Baier B., Stieber N., Dieterich M. Vestibular-evoked myogenic potentials in vestibular migraine. J Neurol 2009;256(9):1447–54. DOI: 10.1007/s00415-009-5132-4
24. Boldingh M.I., Ljøstad U., Mygland A., Monstad P. Vestibular sensitivity in vestibular migraine: vEMPs and motion sickness susceptibility. Cephalalgia 2011;31(11):1211–9. DOI: 10.1177/0333102411409074
25. Taylor R.L., Zagami A.S., Gibson W.P. et al. Vestibular evoked myogenic potentials to sound and vibration: characteristics in vestibular migraine that enable separation from Meniere’s disease. Cephalalgia 2012;32(3):213–25. DOI: 10.1177/0333102411434166
26. Kandemir A., Çelebisoy N., Köse T. Cervical vestibular evoked myogenic potentials in primary headache disorders. Clin Neurophysiol 2013;124(4):779–84. DOI: 10.1016/j.clinph.2012.09.027
27. Kandemir A., Çelebisoy N., Köse T. Perception of verticality in patients with primary headache disorders. J Int Adv Otol 2014;10(2):38–43. DOI: 10.5152/iao.2014.25
28. Замерград М.В. Лечение вестибулярной мигрени. Эффективная фармакотерапия 2021;17(29):32–6. DOI: 10.33978/2307-3586-2021-17-29-32-36 Zamergrad M.V. Vestibular migraine treatment. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2021;17(29):32–6. (In Russ.). DOI: 10.33978/2307-3586-2021-17-29-32-36
29. Масуева С.С., Замерград М.В. Принципы медикаментозного лечения острого вестибулярного головокружения. Медицинский алфавит 2020;1(11):32–5. DOI: 10.33667/2078-5631-2020-11-32-35 Masueva S.S., Zamergrad M.V. Drug treatment of acute vertigo. Meditsinskiy alfavit = Medical Alphabet 2020;1(11):32–5. (In Russ.). DOI: 10.33667/2078-5631-2020-11-32-35
30. Smyth D., Britton Z., Murdin L. et al. Vestibular migraine treatment: a comprehensive practical review. Brain 2022;145(11):3741–54. DOI: 10.1093/brain/awac264
31. Neuhauser H., Radtke A., von Brevern M., Lempert T. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology 2003;60(5):882–3. DOI: 10.1212/01.wnl.0000049476.40047.a3
32. Baloh R.W. Rizatriptan for episodic dizziness in vestibular migraine. Updated 4 November 2021. Available at https://clinicaltrials.gov/ct2/show/study/NCT02447991
33. Maione A. Migraine-related vertigo: diagnostic criteria and prophylactic treatment. Laryngoscope 2006;116(10):1782–6. DOI: 10.1097/01.mlg.0000231302.77922.c5
34. Cassano D., Pizza V., Busillo V. P074. Almotriptan in the acute treatment of vestibular migraine: a retrospective study. J Headache Pain 2015;16(1):A114. DOI: 10.1186/1129-2377-16-S1-A114
35. Schremmer D., Bognar-Steinberg I., Baumann W., Pytel J. Efficacy and tolerability of a fixed combination of cinnarizineand dimenhydrinate in treatment of vertigo. Clin Drug Investig 1999;18:355–68. DOI: 10.2165/00044011-199918050-00003
36. Scholtz A.W., Steindl R., Burchardi N. et al. Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study. Clin Drug Investig 2012:32(6):387–99. DOI: 10.2165/11632410-000000000-00000.
37. Ramón C., Cernuda-Morollón E., Pascual J. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Curr Opin Neurol 2017;30(3):281–6. DOI: 10.1097/WCO.0000000000000440
38. Liu F., Ma T., Che X. et al. The Efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine. Front Neurol 2017;8:524. DOI: 10.3389/fneur.2017.00524
39. Salviz M., Yuce T., Acar H. et al. Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial. Laryngoscope 2016;126(1):169–74. DOI: 10.1002/lary.25445
40. Lempert T., von Brevern M. Vestibular migraine. Neurol Clin 2019;37(4):695–706. DOI: 10.1016/j.ncl.2019.06.003
41. Von Brevern M., Lempert T. Vestibular migraine: treatment and prognosis. Semin Neurol 2020;40(1):83–6. DOI: 10.1055/s-0039-3402067
42. Li G., Xu J., Zhou X. et al. The efficacy of topiramate and flunarizine hydrochloride for prophylactic treatment of vestibular migraine. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2021;35(9):784–7;795. DOI: 10.13201/j.issn.2096-7993.2021.09.004
43. Антоненко Л.М., Парфенов В.А. Реабилитация пациентов с вестибулярными нарушениями. Медицинский совет 2017;(1):33–7. DOI: 10.21518/2079-701X-2017-0-33-37 Antonenko L.M., Parfenov V.A. Rehabilitation of patients with vestibular disorders. Meditsinskiy sovet = Medical Advice 2017;(1):33–7. (In Russ.). DOI: 10.21518/2079-701X-2017-0-33-37
44. Çelebisoy N., Gökçay F., Karahan C. et al. Acetazolamide in vestibular migraine prophylaxis: a retrospective study. Eur Arch Otorhinolaryngol 2016;273(10):2947–51. DOI: 10.1007/s00405-015-3874-4
45. Taghdiri F., Togha M., Razeghi Jahromi S., Refaeian F. Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. Springerplus 2014;3:231. DOI: 10.1186/2193-1801-3-231
Review
For citations:
Masueva S.S., Zamergrad M.V., Grachev S.P. Modern approaches to diagnosis and treatment of vestibular migraine. The Clinician. 2025;19(2):61-67. (In Russ.) https://doi.org/10.17650/1818-8338-2025-19-2-K741
Views:
12
Email this article 